News Feature

Filter By:

Article Type
  • This month we showcase the six-part Nature Careers podcast series, ‘Business of Science,’ which ran in May and June 2021 and aimed to teach new entrepreneurs about the first steps of research commercialization, from registering a patent, to scaling up and beyond.

    • Raveena Bhambra
    News Feature
  • Big pharma dealmaking returns to pre-pandemic levels as companies spend big to develop a range of cancer therapies.

    • Raveena Bhambra
    News Feature
  • Welcome to our May selection of key business of science stories from across Springer Nature’s portfolio of journals. This month we explore some stories based around COVID vaccines and bring to you the first two series of a Nature Careers ‘Business of Science’ podcast that aims to teach new entrepreneurs the first steps of research commercialization and patenting.

    • Raveena Bhambra
    News Feature
  • Plentiful financing and multiple pharma partnerships illustrate the burgeoning interest in applying artificial intelligence tools to drug research and development.

    • Neil Savage
    News Feature
  • Approaches such as gene therapy and nucleic acid-based therapies are emerging in recent deals related to potential treatments for ophthalmic diseases.

    • Biopharma Dealmakers
    News Feature
  • Welcome to our latest round up of key business of science stories from across Springer Nature’s portfolio of journals. This month we look at how biotech funding flourished during the pandemic, and explore the latest information regarding both AstraZeneca’s and Johnson & Johnson’s vaccines in the rollout against COVID-19.

    • Raveena Bhambra
    News Feature
  • Our monthly roundup of 'business of science' stories from across Springer Nature’s portfolio of journals explores the relationships between academia, startups and big pharma, as well as following the progress of the COVID-19 vaccine rollout.

    • Raveena Bhambra
    News Feature
  • A surge of efforts focused on the drug target B cell maturation antigen could transform the treatment of multiple myeloma and help to establish the relative merits and optimization strategies for emerging treatment modalities with wider applications.

    • John Hodgson
    News Feature
  • After a slow start due to the COVID-19 pandemic, oncology dealmaking thrived in 2020 as immuno-oncology fueled a number of high-value drug licensing deals and a string of billion-dollar M&As were announced.

    • Sarah Hardison
    News Feature
  • Our monthly round up of key biopharma business stories from across Springer Nature’s portfolio of journals, including the latest on COVID-19 vaccines and a focus on oncology.

    • Raveena Bhambra
    News Feature
  • In our first monthly round up of the year we explore the big stories from 2020, including key biopharma deals, FDA approvals and IPOs, as well as the extraordinary impact of COVID-19 on science throughout an unusual 12 months.

    • Raveena Bhambra
    News Feature
  • COVID vaccine news dominates our last monthly round-up of articles from Springer Nature research journals, magazines and supplements of the year. The articles explore how the many vaccines in development are affecting the pharmaceutical sector and what challenges lie ahead for their rollout.

    • Raveena Bhambra
    News Feature
  • Biopharma Dealmakers’ monthly round-up continues exploring the most significant biopharma deals of the previous month.

    • Raveena Bhambra
    News Feature